Julien Calderaro

Dr. Julien Calderaro

Département de Pathologie, Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
JCJulien Calderaro
Julien Calderaro
MZMarianne Ziol
Marianne Ziol
VPValérie Paradis
Valérie Paradis
JZJessica Zucman-rossi
Jessica Zucman-rossi

1 January 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
JCJulien Calderaro
Julien Calderaro
FPFlorent Petitprez
Florent Petitprez
EBEtienne Becht
Etienne Becht
ALAlexis Laurent
Alexis Laurent
THTheo Hirsch
Theo Hirsch
CSCatherine Sautès-Fridman
Catherine Sautès-Fridman

28 February 2020 in Hepatology
Verified
Journal Article
Closed access
PDF file
CSCharlie Saillard
Charlie Saillard
BSBenoit Schmauch
Benoit Schmauch
OLOumeima Laifa
Oumeima Laifa
MMMatahi Moarii
Matahi Moarii
STSylvain Toldo
Sylvain Toldo
JCJulien Calderaro
Julien Calderaro

17 June 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
JNJean-Charles Nault
Jean-Charles Nault
YMYoann Martin
Yoann Martin
SCStefano Caruso
Stefano Caruso
THTheo Hirsch
Theo Hirsch
QBQuentin Bayard
Quentin Bayard
JZJessica Zucman-rossi
Jessica Zucman-rossi

8 November 2023 in The Lancet Oncology
Verified
Journal Article
Closed access
QZQinghe Zeng
Qinghe Zeng
CKChristophe Klein
Christophe Klein
SCStefano Caruso
Stefano Caruso
PMPascale Maille
Pascale Maille
DADaniela S Allende
Daniela S Allende
MZMarianne Ziol
Marianne Ziol

14 August 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MMMaxime Meylan
Maxime Meylan
FPFlorent Petitprez
Florent Petitprez
LLLaetitia Lacroix
Laetitia Lacroix
Luca Di TommasoLuca Di Tommaso
Luca Di Tommaso
MRMassimo Roncalli
Massimo Roncalli
JCJulien Calderaro
Julien Calderaro
Purpose: The impact of tertiary lymphoid structures (TLS) in hepatocellular carcinoma (HCC) progression is being extensively investigated. However, their presence during the early steps of human liver carcinogenesis remains unknown. We thus aimed to determine whether TLS are induced in preneoplastic/early hepatic lesions (EHL), and whether they are associated with a particular immune profile.Experimental Design: A series of 127 EHLs (low/high-grade dysplastic nodules, early HCC, and small and progressed HCC) was included in the study. TLSs were investigated by pathologic reviewing. Densities of immune cells were assessed using IHC. A subset of lesions was microdissected and gene expression profiling was performed with a custom NanoString panel.Results: Compared with surrounding cirrhotic nodules, EHL of all stages displayed increased densities of T cells, B cells, and dendritic cells. Immature TLSs were identified in 24% of EHL. Gene expression profiling identified a subset of EHL with elevated mRNA levels of various cytokines involved in immune cells' recruitment and TLS induction. This subgroup of EHL also showed overexpression of genes related to T- and B-cells' activation and antigen presentation, as well as those related to immunosuppression and immune exhaustion.Conclusions: Local immune activation occurs in the very early steps of liver carcinogenesis; however, it may not be fully efficient and paradoxically favor immune evasion and progression to full-blown HCC. These results have implications for the development of anti-HCC chemopreventive strategies in cirrhotic patients.